The American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), the Association for Molecular Pathology (AMP), and the American Society of Clinical Oncology (ASCO) collaborated to develop a clinical practice guideline on the use of molecular marker testing for patients with early and advanced colorectal cancer. This evidence‐based clinical practice guideline will help establish standard molecular marker testing, guide targeted therapy decisions, and advance personalized care for these patients.
Titled "Molecular Biomarkers for the Evaluation of Colorectal Carcinoma: Guideline From the ASCP-CAP-AMP-ASCO," this evidence-based guidance is expected as an early online release published in American Journal of Clinical Pathology, Archives of Pathology & Laboratory Medicine, Journal of Molecular Diagnostics, and the Journal of Clinical Oncology.
The overarching questions that the guideline development panel of experts addressed were:
- What biomarkers are useful to select patients with colorectal cancer (CRC) for targeted and conventional therapies?
- How should tissue specimens be processed for biomarker testing for CRC management?
- How should biomarker testing for CRC management be performed?
- How should molecular testing of CRC be implemented and operationalized?
- Are there emerging genes/biomarkers that should be routinely tested in CRC?
Twenty-one guideline statements were established—eight recommendations, 10 expert consensus opinions, and three "no recommendations." This thorough set of recommendations is intended to streamline processes and contribute to improving patient outcomes.
This guideline will benefit a wide range of stakeholders including oncologists, pathologists, gastroenterologists, nurses, allied health professionals, hospital or laboratory administrators, quality managers, patient advocacy groups, patients, and their families or caregivers.